Skip to menu Skip to content Skip to footer
Professor Gerald Holtmann
Professor

Gerald Holtmann

Email: 

Overview

Background

Prof Holtmann is a Clinical Academic in the field of Gastroenterology & Hepatology and Director of Clinical Innovation. He is also Director of the Department of Gastroenterology & Hepatology at the Princess Alexandra Hospital in Queensland and serves on the Board of Directors of the West Moreton Hospital and Health Service and UQ Healthcare. He is a Fellow of Royal Australian Collge of Physicians (RACP, Sydney), the Royal College of Physicians (RCP, London) and Fellow of the Australian Academy of Health and Medical Sciences (AAHMS, Canberra). Besides his Medical Qualifications he also obtained a Master of Business Administration. After completing the clinical training in Medicine and Gastroenterology at the University of Essen in Germany and the Mayo Clinic in Rochester, Minnesota in the United States, he has gained substantial leadership and managerial experience within the health care setting as Director of large Gastroenterology Departments, CEO and General Manager of a University Hospital and Health Care Facilities and has served on the Board of the University Hospital Essen in Germany. His research is in the field of Neurogastroenterology has resulted in peer reviewed publications in key journal including the NEJM, Lancet, Gastroenterology and Gut. More recently his rersearch focus is on the role of the gut microbiome, mucosal and systemic inflammation and brain-gut interactions.

Availability

Professor Gerald Holtmann is:
Available for supervision
Media expert

Works

Search Professor Gerald Holtmann’s works on UQ eSpace

581 works between 1986 and 2026

1 - 20 of 581 works

2026

Journal Article

Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTION

Luong, Suzanna, Wang, William J., McKillen, Ben, Moy, Naomi, Do, Anh and Holtmann, Gerald (2026). Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTION. Gastroenterology, 170 (6), S-723. doi: 10.1016/s0016-5085(26)01999-2

Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTION

2026

Journal Article

Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP

Shah, Ayesha, Moy, Naomi, Kulin, Dmitrii, Callaghan, Gavin, Fairlie, Thomas, Virgo, Kate, Hansen, Teressa J., Jones, Michael P., Koloski, Natasha A., Thapar, Nikhil and Holtmann, Gerald (2026). Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP. Gastrointestinal Endoscopy, 103 (5), S-1850. doi: 10.1016/s0016-5107(26)04391-9

Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP

2026

Journal Article

Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL

Bredenoord, Albert J., Nguyen, Nam Q., Ho, Vincent, Ko, Hin Hin, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Kolisnik, Tyler, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL. Gastroenterology, 170 (6), S-817. doi: 10.1016/s0016-5085(26)02201-8

Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL

2026

Journal Article

Tu1669 CHRONIC GASTROINTESTINAL SYMPTOMS AND SYSTEMIC COMORBIDITIES IN ADULT PATIENTS WITH HYPERMOBILITY SPECTRUM DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Kulin, Dmitrii, Shah, Ayesha, Fairlie, Thomas, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Aziz, Qasim, Drossman, Douglas A., Jones, Michael P. and Holtmann, Gerald (2026). Tu1669 CHRONIC GASTROINTESTINAL SYMPTOMS AND SYSTEMIC COMORBIDITIES IN ADULT PATIENTS WITH HYPERMOBILITY SPECTRUM DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastrointestinal Endoscopy, 103 (5), S-1946. doi: 10.1016/s0016-5107(26)04599-2

Tu1669 CHRONIC GASTROINTESTINAL SYMPTOMS AND SYSTEMIC COMORBIDITIES IN ADULT PATIENTS WITH HYPERMOBILITY SPECTRUM DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS

2026

Journal Article

Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTION

Luong, Suzanna, Wang, William J., McKillen, Ben, Moy, Naomi, Do, Anh and Holtmann, Gerald (2026). Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTION. Gastrointestinal Endoscopy, 103 (5), S-723. doi: 10.1016/s0016-5107(26)01930-9

Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTION

2026

Journal Article

Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION

Fairlie, Thomas, Celine, Patricia, Shah, Ayesha, Lim, Yenkai, Morrison, Mark and Holtmann, Gerald (2026). Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION. Gastroenterology, 170 (6), S-2457. doi: 10.1016/s0016-5085(26)05814-2

Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION

2026

Journal Article

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( <scp>SIBO</scp> )

Shah, Ayesha, Holtmann, Gerald and Gibson, Peter R. (2026). Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( SIBO ). JGH Open, 10 (5) e70419. doi: 10.1002/jgh3.70419

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( <scp>SIBO</scp> )

2026

Journal Article

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

Wilmes, Sophie, Holtmann, Gerald, Shah, Ayesha and Moy, Naomi (2026). Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW. Gastrointestinal Endoscopy, 103 (5), S-2343. doi: 10.1016/s0016-5107(26)05474-x

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

2026

Journal Article

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

Wilmes, Sophie, Holtmann, Gerald, Shah, Ayesha and Moy, Naomi (2026). Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW. Gastroenterology, 170 (6), S-2343. doi: 10.1016/s0016-5085(26)05543-5

Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW

2026

Journal Article

Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS

Gonsalves, Nirmala, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Ravikumar, Pranali, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS. Gastrointestinal Endoscopy, 103 (5), S-817. doi: 10.1016/s0016-5107(26)02133-4

Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS

2026

Journal Article

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

Ma, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL. Gastroenterology, 170 (6), S-627. doi: 10.1016/s0016-5085(26)01797-x

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

2026

Journal Article

Tu1700 PREVALENCE OF ORTHOSTATIC INTOLERANCE IN PATIENTS WITH DISORDERS OF GUT-BRAIN INTERACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Ayaki, Kana, Shah, Ayesha, Fairlie, Thomas, Kulin, Dmitrii, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Aziz, Qasim, Drossman, Douglas A., Jones, Michael P. and Holtmann, Gerald (2026). Tu1700 PREVALENCE OF ORTHOSTATIC INTOLERANCE IN PATIENTS WITH DISORDERS OF GUT-BRAIN INTERACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology, 170 (6), S-1961. doi: 10.1016/s0016-5085(26)04699-8

Tu1700 PREVALENCE OF ORTHOSTATIC INTOLERANCE IN PATIENTS WITH DISORDERS OF GUT-BRAIN INTERACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

2026

Journal Article

582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

Shah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). 582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI. Gastroenterology, 170 (6), S-2414. doi: 10.1016/s0016-5085(26)05702-1

582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI

2026

Journal Article

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

Ma, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL. Gastrointestinal Endoscopy, 103 (5), S-627. doi: 10.1016/s0016-5107(26)01728-1

400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL

2026

Journal Article

A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior

Shah, Ayesha, Talley, Nicholas J., Knowles, Simon R., Duncanson, Kerith, Koloski, Natasha, Connor, Jason P., Day, Andrew S., Almehdawy, Basil, Basnayake, Chamara, Burgell, Rebecca, Carey, Sharon, Cock, Charles, Daker, Charlotte, Kaushik, Vishal, Kent, Dan, Kellar, Trina, Lane, Katherine, Martin, Neal, Malcolm, Allison, Murphy, Kate Elizabeth, Sharp, Gemma, Tuck, Caroline, Jones, Michael, Thapar, Nikhil and Holtmann, Gerald (2026). A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior. Neurogastroenterology and Motility, 38 (5) e70337. doi: 10.1111/nmo.70337

A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior

2026

Journal Article

Su1303 A COMPARISON OF DIAGNOSTIC METHODOLOGIES FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: ASPIRATE CULTURE, BREATH TESTING AND THE ATMO CAPSULE

Shah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). Su1303 A COMPARISON OF DIAGNOSTIC METHODOLOGIES FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: ASPIRATE CULTURE, BREATH TESTING AND THE ATMO CAPSULE. Gastroenterology, 170 (6), S-2458. doi: 10.1016/s0016-5085(26)05815-4

Su1303 A COMPARISON OF DIAGNOSTIC METHODOLOGIES FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: ASPIRATE CULTURE, BREATH TESTING AND THE ATMO CAPSULE

2026

Journal Article

Su1303 A COMPARISON OF DIAGNOSTIC METHODOLOGIES FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: ASPIRATE CULTURE, BREATH TESTING AND THE ATMO CAPSULE

Shah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). Su1303 A COMPARISON OF DIAGNOSTIC METHODOLOGIES FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: ASPIRATE CULTURE, BREATH TESTING AND THE ATMO CAPSULE. Gastrointestinal Endoscopy, 103 (5), S-2458. doi: 10.1016/s0016-5107(26)05746-9

Su1303 A COMPARISON OF DIAGNOSTIC METHODOLOGIES FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: ASPIRATE CULTURE, BREATH TESTING AND THE ATMO CAPSULE

2026

Journal Article

Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL

Bredenoord, Albert J., Nguyen, Nam Q., Ho, Vincent, Ko, Hin Hin, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Kolisnik, Tyler, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL. Gastrointestinal Endoscopy, 103 (5), S-817. doi: 10.1016/s0016-5107(26)02132-2

Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL

2026

Journal Article

Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP

Shah, Ayesha, Moy, Naomi, Kulin, Dmitrii, Callaghan, Gavin, Fairlie, Thomas, Virgo, Kate, Hansen, Teressa J., Jones, Michael P., Koloski, Natasha A., Thapar, Nikhil and Holtmann, Gerald (2026). Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP. Gastroenterology, 170 (6), S-1850. doi: 10.1016/s0016-5085(26)04460-4

Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP

2026

Journal Article

Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS

Gonsalves, Nirmala, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Ravikumar, Pranali, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS. Gastroenterology, 170 (6), S-817. doi: 10.1016/s0016-5085(26)02202-x

Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS

Funding

Current funding

  • 2022 - 2026
    ARC Training Centre for Behavioural Insights for Technology Adoption (BITA) (ARC Industrial Transformation Training Centre Administered by QUT)
    Queensland University of Technology
    Open grant

Past funding

  • 2021 - 2025
    A practice change for patients with severe chronic, clinically unexplained gastrointestinal symptoms: A randomised, controlled intervention to assess efficacy and cost-effectiveness
    NHMRC IDEAS Grants
    Open grant
  • 2020 - 2024
    Modulation of the Gastrointestinal Microbiome with probiotics and subsequent Methane production as a novel approach to treat constipation: A Proof of Principle Study (TRI Sport Grant led by PAH)
    Metro South Hospital and Health Service
    Open grant
  • 2020 - 2025
    Targeting the gut microbiome as a treatment for Primary Sclerosing Cholangitis: The Queensland Clinical Network Study
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2019 - 2024
    Centre for Research Excellence in Digestive Health (NHMRC CRE administered by University of Newcastle)
    University of Newcastle
    Open grant
  • 2016
    Establishing a gnotobiotic germ-free mouse facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016
    The Australian human microbiota project-microbe isolation facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2015 - 2018
    Pathophysiology of functional dyspepsia: Integration of upper gut function, inflammation and a systems biology approach.
    NHMRC Project Grant
    Open grant
  • 2014 - 2017
    Functional dyspepsia: Characterisation of the immunopathology and testing a novel therapeutic strategy (NHMRC Project Grant administered by the University of Newcastle)
    University of Newcastle
    Open grant

Supervision

Availability

Professor Gerald Holtmann is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    IBD and mental health tools: a holistic approach to discovery and appropriate tool.

    Principal Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    Effects the COVID-19 pandemic on the outcome and management of highly prevalent gastrointestinal conditions

    Principal Advisor

    Other advisors: Dr Ayesha Shah

  • Doctor Philosophy

    The role of the gut microbiome in alcohol related liver disease

    Associate Advisor

    Other advisors: Professor Jason Connor, Honorary Professor Paul Clark

  • Doctor Philosophy

    Study of TOfacitinib for the treatment of chronic Pouchitis

    Associate Advisor

    Other advisors: Associate Professor Jakob Begun

  • Doctor Philosophy

    Investigating the Role of Exercise in Managing Disorders of the Gut Brain Interaction

    Associate Advisor

    Other advisors: Professor Jeff Coombes

  • Doctor Philosophy

    Targeting the gastrointestinal mucosa associated microbiome to improve clinical outcomes

    Associate Advisor

    Other advisors: Dr Ayesha Shah

Completed supervision

Media

Enquiries

Contact Professor Gerald Holtmann directly for media enquiries about:

  • colon cancer screening
  • Gastroenterology
  • Gut Health
  • Microbiome
  • Neurogastroenterology

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au